摘要
目的观察唑来膦酸注射液治疗绝经后骨质疏松的急性期不良反应,并分析急性期不良反应的影响因素。方法选取绝经后骨质疏松患者84例,所有患者给予5 mg唑来膦酸注射液治疗,观察应用唑来膦酸注射液后72 h内出现的急性期不良反应;并应用Logistic回归分析探索急性期不良反应的可能影响因素。结果共有39例患者出现急性期不良反应,总不良反应率为46.43%,其中发热33例(39.29%),流感样症状23例(27.38%),头痛15例(17.86%),肌肉关节痛25例(29.76%),胃肠道反应6例(7.14%),血小板减少1例(1.19%)。单因素分析显示急性期不良反应与年龄、BMI、用药前服用非甾体类消炎药(NSAIDs)及既往骨吸收抑制剂应用史有关(P<0.05);多因素Logistic回归分析显示,高BMI、用药前服用NSAIDs及骨吸收抑制剂应用史为急性期不良反应的保护性因素(P<0.05)。结论唑来膦酸注射液治疗绝经后骨质疏松急性期不良反应较为常见,但症状较轻,一般可自行缓解;高BMI、用药前服用NSAIDs及骨吸收抑制剂应用史可减少急性期不良反应的发生。
Objective To observe acute phase adverse responses after zoledronic acid injection treatment for postmenopausal osteoporo- sis, analyze the influencing factors. Methods A total of 84 patients with postmenopausal osteoporosis were selected and treated by 5 mg zoledronic acid intravenously. The acute phase adverse responses were observed within 72 hours, then the probable influencing factors were analyzed by logistic regression analysis. Results The total incidence rate of acute phase adverse response was 46.43% （39 patients）, 33 patients with fever （39.29%）, 23 patients with influenza-like symptoms （27.38%）, 15 patients with headache （ 17. 86% ）, 25 patients with muscle and joint pain （29.76%）, 6 patients with gastrointestinal discomforts （7.14%）, and 1 patient with thromboeytopenia （ 1.19% ） were included. Univariate analysis showed that acute phase adverse responses were eorrelated with age, body mass index （BMI）, administration of NSAIDs before treatment and usage history of bone resorting inhibitors （ P〈0. 05 ） ; multivariate analysis showed that high BMI, administration of NSAIDs before treatment and usage history of bone resorting inhibitors were protective factors of acute phase adverse responses （ P〈0.05 ） . Conclusion The acute phase adverse responses occur frequently after zoledronic acid treatment for postmenopansal osteoporosis, but the symptoms are mild and transient. High BMI, administration of NSAIDs before treatment and usage history of bone resorting inhibitors can reduce acute phase adverse responses.
出处
《中国妇幼保健》
CAS
2016年第22期4800-4802,共3页
Maternal and Child Health Care of China
